Pipeline & Launch Brand Alerts — November 2025 (Insights Hub Launch)
We tracked 20+ major updates in November, including multiple FDA approvals, NDA/BLA submissions and positive Phase 3 readouts — many tied to assets projected to generate $1B+ in peak annual sales. Plus: the launch of the Athena BDA Pharma Insights Hub.
We’ve just launched the Athena BDA Pharma Insights Hub — a subscriber portal where we publish the complete version of our monthly pipeline alerts, FDA approvals and late-stage drug intelligence.
Explore the Insights Hub. Below is the lite version of the November newsletter.
In November, we tracked 20+ major updates, including multiple FDA approvals, NDA/BLA submissions and positive Phase 3 readouts — many linked to assets projected to generate $1B+ in peak annual sales.
Hot Tip #1 — Bezuclastinib | Cogent
Peak-sales consensus: $5B+ · Stage: Positive Phase 3 data (GIST)
Cogent reported strong Phase 3 results for bezuclastinib in GIST, delivering a 46% objective response rate and materially outperforming standard-of-care sunitinib. An FDA submission is planned in H1 next year, positioning the asset to challenge established TKIs.
Athena BDA insight: Priority Score 1 — blockbuster launch setup, with significant commercial hiring already underway.
Hot Tip #2 — Asundexian | Bayer
Peak-sales consensus: ~$3B · Stage: Positive Phase 3 data (secondary stroke prevention)
Bayer’s oral FXIa inhibitor delivered a clean Phase 3 win, reducing stroke risk without increasing major bleeding. The readout restores confidence in the FXIa class and repositions the asset as a meaningful pipeline win.
Athena BDA insight: Priority Score 1 — multiple launch leaders identified following the positive data.
Hot Tip #3 — Fenebrutinib | Roche
Peak-sales consensus: multi-billion · Stage: Positive Phase 3 data (multiple sclerosis)
Positive Phase 3 data across two MS studies positions this oral BTK inhibitor as a leading contender in a space where several competitors have struggled to deliver.
Athena BDA insight: Priority Score 1 — strong MS-focused contact pool already mapped across the organisation.
What else moved this month?
- 🦉 A first-in-class oral lipid-lowering therapy matched injectable efficacy in Phase 3 trials, setting up global regulatory submissions and potential disruption in primary care.
- 🦉 A novel hypertension mechanism delivered best-in-class blood pressure reductions in treatment-resistant patients, strengthening its position versus late-stage competitors.
- 🦉 A late-stage autoimmune asset showed statistically significant Phase 3 efficacy in a disease with no approved systemic therapies, reinforcing multi-billion-dollar potential.
- 🦉 Multiple FDA approvals across rare disease, oncology and RNA therapeutics, including a company’s first commercial launch and continued momentum from established rare-disease players.
Want the full November analysis — including drug names, sales projections, source links and commercial-readiness insight? It’s all available inside the Athena BDA Pharma Insights Hub.